Embodiments relate to microparticles containing moxidectin, and a preparation method thereof. Unlike conventional heartworm prevention drugs that have a short half-life and thus require daily or monthly administration, moxidectin is continuously released for at least three months and thus the effect of preventing heartworms can be maintained for at least three months when the microparticles containing moxidectin are administered. In addition, microparticles which have a constant average diameter and a narrow diameter distribution are prepared so that initial over-release of moxidectin is prevented when the microparticles are administered, the release of the drug can be controlled to keep constant the concentration of moxidectin that is valid for at least three months, and foreign body sensation and pain can be reduced when the microparticles are applied in the form of an injection.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present invention relates to microparticles comprising tirzepatide or a pharmaceutically acceptable salt thereof and a manufacturing method therefor, wherein the content of tirzepatide or a pharmaceutically acceptable salt thereof is increased in the microparticles, thereby increasing the loading amount of a drug in the microparticles and exhibiting an effect of continuously releasing tirzepatide or a pharmaceutically acceptable salt thereof from the microparticles without initial over-release and lag time, thus preventing an excessive decrease in bioavailability. In addition, when the microparticles are used as a subcutaneous injection, the amount of microparticles included for one injection can be reduced, thereby reducing pain at the site of administration and causing no inflammatory response.
An embodiment relates to a novel long-acting injectable composition for preventing or treating androgenetic alopecia containing finasteride. The injectable composition is capable of inhibiting type II 5α-reductase for one month or more with a single injection, thereby limiting the conversion of testosterone to DHT and inhibiting androgen-mediated hair follicle miniaturization. In addition, the injectable composition may increase the mean elimination half-life (t1/2el) of finasteride after in vivo injection, thereby increasing the stability of finasteride, and exhibiting a more predictable and uniform therapeutic effect compared to oral dosage forms.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
5.
NOVEL LONG-ACTING INJECTABLE COMPOSITION COMPRISING FINASTERIDE FOR PREVENTION OR TREATMENT OF ANDROGENETIC ALOPECIA
1/2el1/2el) of finasteride can be increased to enhance stability and provide more predictable and uniform therapeutic effects compared to oral formulations.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
6.
METHOD FOR PREPARING MICROPARTICLES CONTAINING MOXIDECTIN AND SUSTAINED RELEASE INJECTABLE COMPOSITION COMPRISING MICROPARTICLES PREPARED BY SAME PREPARATION METHOD
Embodiments relate to microparticles containing moxidectin and a method for preparing same. Unlike conventional drugs for preventing heartworm disease, which have a short half-life and require daily or monthly administration, when the microparticles containing moxidectin are administered, moxidectin is continuously released for 3 months or longer, and thus, a heartworm disease preventive effect can be maintained. In addition, by preparing microparticles having a constant average particle diameter and a narrow diameter distribution width, even when the microparticles are administered, the initial over-release of moxidectin is prevented, and the release of the drug is controlled so that a concentration of moxidectin effective for three months or longer can be kept constant, and when the microparticles are applied as an injection, foreign body sensation and pain can be reduced.
The present invention relates to a sustained-release injection composition comprising exenatide and a method for preparing same. The sustained-release injection composition enables exenatide to be continuously released in the body for 1-2 months with a single injection, thus making it possible to reduce the number of administrations and improve the convenience of administration. In addition, since the sustained-release injection composition contains exenatide in microparticles having a uniform particle size, long-term sustained release of exenatide can be achieved, and thus the bio-absorption rate of exenatide can be increased compared to conventional injectable formulations comprising exenatide.
The present invention relates to a liposome containing semaglutide or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising same, and a method for preparing same. Semaglutide or a pharmaceutically acceptable salt thereof, which usually exhibits low absorption, can be encapsulated within the liposome, thereby enhancing the absorption rate thereof. In addition, the liposome comprising semaglutide or a pharmaceutically acceptable salt thereof can exhibit excellent effects in regulating blood glucose and preventing and treating obesity by increasing bioavailability. Furthermore, the present invention relates to a method for preparing liposomes containing semaglutide or a pharmaceutically acceptable salt thereof that are uniform in size and exhibit an excellent encapsulation rate and excellent stability.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
The present invention relates to: a sustained-release injectable composition for treating or preventing neurological disorders; and a method for preparing same. The sustained-release injectable composition uses microparticles containing cannabidiol and continuously releases the cannabidiol for at least one month, and thus can be effective in treating or preventing neurological disorders. In addition, the sustained-release injectable composition includes cannabidiol, which is non-toxic and can be used continuously for a long time due to the absence of side effects from long-term use, and thus can exhibit a therapeutic or prophylactic effect on neurological disorder patients for at least one month through a single injection. Therefore, the sustained-release injectable composition can greatly improve the convenience of administration.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
10.
MICROPARTICLES COMPRISING SEMAGLUTIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR
The present invention relates to microparticles comprising semaglutide or a pharmaceutically acceptable salt thereof, and a preparation method therefor. When the microparticles are injected into the body as an injection, continuous release thereof for 4 weeks or more is possible without initial over-release of semaglutide or a pharmaceutically acceptable salt thereof. In addition, the present invention relates to a method for preparing microparticles having a donut shape in which a hole is formed in the center thereof at the cross-section of the microparticles, and having uniform diameters.
A composition for sustained-release injection comprising deslorelin, can prevent initial over-release by adjusting the release rate of deslorelin at a target site and can exhibit the effect of deslorelin for 1 month or more by being exposed in an amount enough to show the effect of deslorelin. Further, the microparticles can prepare microparticles that have a uniform particle size and are capable of exhibiting the effect of continuously releasing deslorelin for a long time.
The present invention relates to microparticles containing cannabidiol, wherein the microparticles can possess improved stability by prevention of the oxidation of cannabidiol in the microparticles since the oxidation of cannabidiol contained in the microparticles causes a deterioration in the stability of the microparticles. The present invention also relates to a manufacturing method for microparticles with a uniform particle size, which contains cannabidiol and a biodegradable polymer, cannabidiol being uniformly contained in the microparticles.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
13.
MICROPARTICLES CONTAINING MOXIDECTIN, AND PREPARATION METHOD THEREFOR
The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 45-130 μm, depending on the type of polymer. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3 months to 6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.
The present invention relates to a spiral-structured chip for preparing lipid nanoparticles, and a method for preparing lipid nanoparticles by using same. The mixing efficiency of an aqueous solution that contains a nucleic acid and an oil solution that contains a lipid is increased such that uniform lipid nanoparticles can be formed by self-assembly at the interface between the aqueous solution and the oil solution. In addition, the provided preparation method can efficiently prepare lipid nanoparticles of a uniform shape and size by using the spiral-structured chip for preparing lipid nanoparticles.
B01F 25/00 - Mélangeurs à écoulementMélangeurs pour matières tombantes, p. ex. particules solides
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p. ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
15.
METHOD FOR PRODUCING SUSTAINED-RELEASE MICRO PARTICLES CONTAINING ATORVASTATIN AND SALT THEREOF, AND SUSTAINED-RELEASE MICRO PARTICLES PRODUCED THEREBY
The present invention relates to a method for producing sustained-release micro particles containing atorvastatin, and sustained-release micro particles produced thereby. The present invention relates to sustained-release micro particles that allow for increasing the encapsulation efficiency of atorvastatin and improving the removal of residual solvents and contains atorvastatin with uniform diameters. Additionally, the sustained-release micro particles containing atorvastatin produced by the aforementioned method can continuously release atorvastatin for one or two months with a single administration, thus improving dosing convenience.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
The present invention relates to lipid nanoparticles comprising low-concentration ionizable lipids, and a preparation method therefor, and has a low amount of ionizable lipids in the lipid nanoparticles such that cytotoxicity can be reduced. In addition, according to the preparation method for lipid nanoparticles, of the present invention, the lipid nanoparticles have a uniform spherical shape and an excellent nucleic acid encapsulation rate, and, when lipid nanoparticles are prepared, amounts of non-ionized lipids and fusogenic lipids are increased such that a plurality of lipid nanoparticles can be prepared using an amount of nucleic acids which are the same as those used for conventional lipid nanoparticles, and, when the same nucleic acids are injected, the number of lipid nanoparticles to be injected into the body is increased such that the protein expression level of the nucleic acids can be increased.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
17.
SUSTAINED-RELEASE INJECTABLE COMPOSITION CONTAINING NALTREXONE AND METHOD FOR PREPARING SAME
A sustained-release injectable composition containing naltrexone, and a method for producing the same are described. The composition may prevent the initial burst release of naltrexone by controlling the release rate of naltrexone at a target site, and maintain a plasma naltrexone concentration sufficient to exhibit the effect of naltrexone by releasing naltrexone continuously for one month. In addition, the production method is capable of producing microparticles that are homogeneous and of good quality while having high encapsulation efficiency for naltrexone, a poorly soluble drug.
The present invention relates to an emulsion comprising dexamethasone, a preparation method therefor, and microparticles comprising dexamethasone, the emulsion and microparticles having a regular surface and a perfect spherical shape, and having dexamethasone evenly distributed. In addition, when administered in the body, there is no initial excessive release, and dexamethasone can be continuously released for a long time.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
19.
METHOD FOR REMOVING ORGANIC SOLVENT REMAINING IN MICROPARTICLES BY USING COMPLEX AQUEOUS-PHASE SOLUTION
The present invention relates to a method for removing an organic solvent remaining in microparticles by using a complex aqueous-phase solution. The stirring time in a manufacturing process for the mass production of microparticles containing drugs and a process for removing an residual organic solvent can be shortened, the organic solvent can be efficiently removed, and the generation of related substances can be prevented.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
B01J 13/00 - Chimie des colloïdes, p. ex. production de substances colloïdales ou de leurs solutions, non prévue ailleursFabrication de microcapsules ou de microbilles
A method for producing microparticles containing a poorly soluble drug, and microparticles produced by the method are proposed. According to the method for preparing microparticles, it is possible to produce microparticles that are uniform and of good quality and have high encapsulation efficiency for the poorly soluble drug and low contents of residual organic solvents, by using at least two organic solvents.
The present disclosure relates to a method for manufacturing lipid nanoparticles and an apparatus for manufacturing the same, which are capable of increasing a production yield in a subsequent eradication filtration process and the like by not requiring a separate process for sorting the manufactured lipid nanoparticles.
The present disclosure relates to a method for manufacturing lipid nanoparticles and an apparatus for manufacturing the same, which are capable of increasing a production yield in a subsequent eradication filtration process and the like by not requiring a separate process for sorting the manufactured lipid nanoparticles.
In addition, by deviating from an existing optimal drug and lipid ratio, a content of ionizable lipid that causes a problem of toxicity when injected into the body may be lowered, and uniform-sized lipid nanoparticles may be manufactured.
09 - Appareils et instruments scientifiques et électriques
Produits et services
(1) Agitators for chemical processing; calcining machines for chemical processing; Separating machines for chemical processing; Blending machines for chemical processing; Dissolving machines for chemical processing; disintegrators for chemical processing; emulsifying machines for chemical processing; extracting machines for chemical processing; kneading machines for chemical processing; presses for chemical processing; sintering machines for chemical processing; sorting machines for chemical processing; grinding machines for chemical processing; Machines for manufacturing drug delivery systems, namely, sustained-release injectables and lipid-based nanoparticles; Industrial mixer for mixing liquids in the pharmaceutical and chemical industries; Filtering machines for chemical processing
(2) Laboratory chemical reactors; liquid dispensing machines for dispensing pre-measured amounts; Chemical reaction apparatus, namely, reaction vessels and reservoir vessels; Gas mixers for laboratory use; laboratory photochemical reactors; Laboratory scales and balances; Laboratory filters, namely, syringe filters, disc members, vacuum filters; Apparatus for synthesizing protein and peptide; Laboratory chemical reactors; Bioreactors for laboratory use; bioreactors for cell culturing
09 - Appareils et instruments scientifiques et électriques
Produits et services
agitators for chemical processing; separating machines for chemical processing; blending machines for chemical processing; chemical machines for industrial purposes; machines for drug delivery system manufacturing; handling machines, automatic, for pharmaceutical processing; agitators; electromechanical machines for chemical industry; filtering machines for chemical processing. chemical reactors; reaction vessels for chemical processing; apparatus and instruments for physics; chemistry apparatus and instruments; laboratory mixers; pharmaceutical chemical reactors; apparatus and instruments for weighing; laboratory filters; apparatus for synthesizing protein and peptide; laboratory apparatus for controlling process; bioreactors for research use.
09 - Appareils et instruments scientifiques et électriques
Produits et services
Agitators for chemical processing; reaction vessels for chemical processing, namely, industrial chemical reactors; separating machines for chemical processing; blending machines for chemical processing; chemical machines for industrial purposes, namely, filtering machines for chemical processing, chemical fiber drying machines, sorting machine for chemical processing, blending machines for chemical processing, calcining machines for chemical processing, agitators for chemical processing, extracting machines for chemical processing; electrospinning machines for manufacturing fiber-based medical devices and pharmaceutical products in the nature of artificial tissue scaffolds and matrices, artificial scaffolds and matrices for local drug delivery, artificial scaffolds and matrices for targeted drug delivery, and artificial extracellular matrices; machine used for process filtration in the pharmaceutical industry; agitators for circulating liquid media; electromechanical machines for chemical industry, namely, blending machines for chemical processing, chemical processing machines for extracting, sintering, emulsifying, calcining and granulating chemicals; filtering machines for chemical processing Laboratory chemical reactors; apparatus and instruments for physics, namely, gravity measuring instruments, voltmeters, altimeters, densimeters, concentration meters and actinometers; chemistry apparatus and instruments, namely, flasks for laboratory use, laboratory pipettes, laboratory filters; laboratory mixers, namely, homogenizers and powder mixers for laboratory use, liquid mixers for laboratory use; pharmaceutical chemical reactors, namely, laboratory chemical reactors; apparatus and instruments for weighing; laboratory filters; apparatus for synthesizing protein and peptide; laboratory apparatus for controlling process, namely, chemical processing device; bioreactors for research use
25.
SUSTAINED-RELEASE INJECTABLE COMPOSITION FOR TREATING OR PREVENTING INFLAMMATORY DISEASE, AND METHOD FOR PREPARING SAME
The present invention relates to a sustained-release injectable composition for treating or preventing an inflammatory disease, and to a method for preparing same. The present invention may continuously release cannabidiol for more than one month by using microparticles containing cannabidiol, thereby having the effect of treating or preventing an inflammatory disease. In addition, the present invention provides the sustained-release injectable composition comprising cannabidiol which is non-toxic and can be used continuously for a long time as there are no side effects from long-term use, and thus may provide, by using a single injection, the effect of treating or preventing an inflammatory disease for more than one month, thereby greatly improving the convenience of administration.
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to a sustained-release injectable composition containing dutasteride, which may exhibit a continuous dutasteride release effect for at least three months, even when the dose of dutasteride that is taken is equal to or less than the pre-existing AVODART® which is taken once a day, and thus may exhibit a continuous drug taking effect for a long time from one injection. In addition, the sustained-release injectable composition may exhibit a continuous therapeutic effect for benign prostatic hyperplasia, prostate cancer and hair loss for at least three months, and microparticles contained in the sustained-release injectable composition have a predetermined average diameter, and thus drug release may be controlled so that an effective drug concentration may be constantly maintained, and a foreign body sensation and pain may be reduced when the sustained-release injectable composition is administered as an injection to a patient.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
27.
MICROSPHERE PRODUCING SYSTEM AND MICROSPHERE PRODUCING METHOD
A system for producing a microsphere includes a first raw material storing to store a first raw material is stored, a second raw material storing part to store a second raw material including a solvent, a biodegradable polymer, and a drug, an emulsion generating part to continuously form an emulsion including the first raw material of a continuous phase and the second raw material of a dispersed phase, a first solvent extracting and removing part to accommodate the emulsion formed from the emulsion generating part, and extract and remove the solvent from the dispersed phase of the emulsion to form a microsphere, and a second solvent extracting and removing part spaced apart from the first solvent extracting and removing part, to accommodate the emulsion formed from the emulsion generating part, and extract and remove the solvent from the dispersed phase of the emulsion to form a microsphere.
A solvent-removing apparatus according to an embodiment includes a tank body accommodating an emulsion including first source material in a continuous phase and second source material in a dispersed phase, a fluid supply unit for supplying fluid into the tank body to cause the emulsion to circulate, and a discharge unit for discharging the gas in the tank body to the outside.
B01D 35/027 - Filtres adaptés à des endroits particuliers, p. ex. conduites, pompes, robinets montés de façon rigide dans ou sur des récipients ou des réservoirs
29.
METHOD FOR PREPARING MICROPARTICLES CONTAINING MOXIDECTIN AND SUSTAINED-RELEASE INJECTABLE COMPOSITION COMPRISING MICROPARTICLES PREPARED BY SAME PREPARATION METHOD
The present invention relates to microparticles containing moxidectin and a method for preparing same. Unlike conventional drugs for preventing heartworm disease, which have a short half-life and require daily or monthly administration, when the microparticles containing moxidectin are administered, moxidectin is continuously released for 3 months or longer, and thus, a heartworm disease preventive effect can be maintained. In addition, by preparing microparticles having a constant average particle diameter and a narrow diameter distribution width, even when the microparticles are administered, the initial over-release of moxidectin is prevented, and the release of the drug is controlled so that a concentration of moxidectin effective for three months or longer can be kept constant, and when the microparticles are applied as an injection, foreign body sensation and pain can be reduced.
The present invention relates to microparticles containing moxidectin, and a preparation method thereof. Unlike conventional heartworm prevention drugs that have a short half-life and thus require daily or monthly administration, moxidectin is continuously released for at least three months and thus the effect of preventing heartworms can be maintained for at least three months when the microparticles containing moxidectin are administered. In addition, microparticles which have a constant average diameter and a narrow diameter distribution are prepared so that initial over-release of moxidectin is prevented when the microparticles are administered, the release of the drug can be controlled to keep constant the concentration of moxidectin that is valid for at least three months, and foreign body sensation and pain can be reduced when the microparticles are applied in the form of an injection.
The present disclosure provides a sustained formulation for prevention or treatment of autoimmune disease, comprising microparticles comprising naltrexone or pharmaceutically acceptable salts thereof, and biodegradable polymers, and a method using the same. Accordingly, it may be used to prevent or treat autoimmune diseases for a prolonged period of time with a single administration.
A lipid nanoparticles manufacturing chip includes a mixer unit for forming a mixed solution by mixing a first raw material containing an active ingredient and a second raw material containing a lipid, a dilution unit that is connected to the mixer unit and dilutes the mixed solution using a diluent solution to make a diluted mixed solution, and a concentration unit connected to the dilution unit and for obtaining a concentrated solution by concentrating lipid nanoparticles (LNP) from the diluted mixed solution.
B01F 33/301 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
The present invention relates to a sustained-release injectable composition containing deslorelin, wherein the release rate of deslorelin is controlled at a target site so that initial over-release is prevented and an amount sufficient for the effects of deslorelin to be exhibited is exposed, and thus the effect of the deslorelin can be exhibited for at least one month. Also, the microparticles can be prepared to have a uniform particle size and continuously exhibit a deslorelin releasing effect for a long period of time.
A composition for sustained-release injection comprising deslorelin, can prevent initial over-release by adjusting the release rate of deslorelin at a target site and can exhibit the effect of deslorelin for 1 month or more by being exposed in an amount enough to show the effect of deslorelin. Further, the microparticles can prepare microparticles that have a uniform particle size and are capable of exhibiting the effect of continuously releasing deslorelin for a long time.
This solvent removing apparatus comprises: a container for receiving an emulsion including a first raw material of a continuous phase and a second raw material of a dispersed phase; a filter unit that is connected to the inside of the container, receives the emulsion from the container, filters out a portion of the continuous phase of the emulsion and a solvent in the continuous phase, and then provides the remaining emulsion back to the container; a supply unit that is connected to the inside of the container and supplies the first raw material into the container; and a stirring means that generates flow in the emulsion inside the container, thereby stirring the emulsion.
A solvent removing apparatus includes a container containing an emulsion comprising a first raw material of a continuous phase and a second raw material of a dispersed phase, an impeller rotating in the container to stir the emulsion, and a foam breaker spaced apart from the impeller on an upper portion of the impeller, positioned below a surface of the emulsion to be submerged in the emulsion when the emulsion is calm, and rotating to reduce foam generated during stirring of the emulsion.
B01D 19/02 - Dispersion ou prévention de la mousse
B01F 27/191 - Agitateurs avec plusieurs éléments de mélange montés en séquence sur un même axe avec des éléments similaires
B01F 27/86 - Mélangeurs à agitateurs tournant dans des récipients fixesPétrins avec des agitateurs tournant autour d'un axe sensiblement vertical coopérant avec les déflecteurs ou les chicanes fixés au récipient
B01F 35/53 - Récipients de mélange caractérisés par la configuration de l'intérieur, p. ex. chicanes pour faciliter le mélange des composants
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
37.
Microparticles containing leuprolide and method for producing the same
The present invention provides microparticles containing leuprolide and a method for producing the same. When the microparticles are administered by injection, they may lower pain due to their small size, control the release rate of leuprolide at a target site, prevent excessive release of leuprolide at an initial stage, enable exposure to a sufficient amount of the drug to exhibit the effect of leuprolide, and exhibit the effect of leuprolide for 1 month or more. The present invention also provides a method for producing microparticles, in which the microparticles have a uniform particle size and a smooth surface and may exhibit the effect of releasing leuprolide sustainably over a long period of time.
The present invention relates to microparticles containing leuprolide and a preparation method thereof. When the microparticles are administered as an injection, the pain of the injection may be reduced due to the small size of the microparticles, the release rate of leuprolide is adjusted at a target site to prevent initial over-release, and the effects of leuprolide are exhibited, and thus the target site is exposed to a sufficient amount of the drug, and the effects of leuprolide may be exhibited for one month or longer. In addition, the present invention relates to a method for preparing the microparticles, wherein the microparticles have a uniform size and a smooth surface, and can continually exhibit the effects of leuprolide release for a long period of time.
The present invention pertains to: a method for preparing microparticles containing poorly soluble drugs; and microparticles prepared by the method. The method for preparing microparticles uses two or more organic solvents and can thus be used to prepare microparticles having uniform and excellent quality, a high encapsulation rate of poorly soluble drugs, and a small amount of residual organic solvents.
The present invention relates to a sustained-release injectable composition containing naltrexone, and a method for preparing same, wherein the release rate of naltrexone is controlled at a target site to prevent initial over-release, and naltrexone is continuously released for one month, such that blood concentrations sufficient to exhibit effects caused by naltrexone can be maintained. In addition, the present invention relates to a manufacturing method enabling microparticles having a high encapsulation rate of naltrexone, which is a poorly soluble drug, to be produced while the microparticles are homogeneous and of excellent quality.
A microparticle producing system using microfluidics and a controlling method thereof, and specifically, to a microparticle producing system that may stably transport droplets produced using microfluidics without agglomeration or destruction, compared to the conventional art, and a method of controlling the microparticle producing system to transport the droplets more stably in the microparticle producing system. By the microparticle producing system and the controlling method thereof, which are disclosed herein, droplets produced by the microparticle producing system using microfluidics may be stably transported without agglomeration or destruction, resulting in more effective microparticle production.
This chip for preparing lipid nanoparticles comprises: a first raw material supply channel; a second raw material supply channel; and a mixer that is connected to the first raw material supply channel and the second raw material supply channel and mixes a first raw material supplied through the first raw material supply channel and a second raw material supplied through the second raw material supply channel. The mixer includes a first stabilization part and a first mixing part which is connected to the first stabilization part and in which the first raw material is mixed with the second raw material. More of the mixing of the first raw material and the second raw material takes place in the first mixing part than in the first stabilizing part.
B01F 33/3011 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux utilisant un courant de gainage d'un fluide entourant un courant central d'un autre fluide, p. ex. pour réduire la section transversale du courant central ou pour produire des gouttelettes à partir du courant central
B01F 25/00 - Mélangeurs à écoulementMélangeurs pour matières tombantes, p. ex. particules solides
The present disclosure provides a sustained formulation for prevention or treatment of autoimmune disease, comprising microparticles comprising naltrexone or pharmaceutically acceptable salts thereof, and biodegradable polymers, and a method using the same. Accordingly, it may be used to prevent or treat autoimmune diseases for a prolonged period of time with a single administration.
A chip for preparing lipid nanoparticles comprises: a mixer unit which mixes a first raw material including mRNA and a second raw material including lipids to form a mixed solution; a dilution unit which is connected to the mixer unit and dilutes the mixed solution by using a diluent; and a concentration unit which is connected to the dilution unit and concentrates lipid nanoparticles (LNPs) from the diluted mixed solution to obtain a concentrate.
B01F 33/301 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux
B01F 25/00 - Mélangeurs à écoulementMélangeurs pour matières tombantes, p. ex. particules solides
The present disclosure provides sustained-release microparticles comprising a biodegradable polymer and a drug, wherein the biodegradable polymer and the drug are uniformly distributed throughout the particles, and the microparticles do not show an initial excessive release of the drug, and are composed of uniform-sized particles having a particle size distribution width of 35 microns or less analyzed by a particle size analyzer and a specific surface area of the microparticles of 0.75×10−1 to 2.0×10−1 m2/g, thereby exhibiting a sustained release pattern of the drug. The injection composition comprising the drug contained in such microparticles can control the release of the drug for a selected period during injection administration to release an effective drug concentration constantly, and when formulated as an injection product, can reduce foreign body sensation and pain to the subject to enable an injection formulation with high compliance to be provided.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
The present invention relates to a lipid nanoparticle preparation method and a preparation apparatus therefor. Since a separate process for selecting prepared lipid nanoparticles is not required, production yield can be increased in a sterilization and filtration process and the like of a downstream stage. In addition, the present invention can prepare lipid nanoparticles which have a uniform size and have, by deviating from a conventional optimum drug and lipid ratio, the reduced amount of ionized lipid of which toxicity is problematic when administered into the body.
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
B82Y 40/00 - Fabrication ou traitement des nanostructures
47.
SUSTAINED FORMULATION FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE CONTAINING LOW-DOSE NALTREXONE AND METHOD USING SAME
Provided are: a sustained formulation, for prevention or treatment of an autoimmune disease, containing naltrexone or a pharmaceutically acceptable salt thereof, and microparticles comprising a biodegradable polymer; and a method using same. The present invention may be used for continuous and long-term prevention or treatment of an autoimmune disease by means of a single administration.
The present disclosure provides sustained-release microparticles comprising a biodegradable polymer and a drug, wherein the biodegradable polymer and the drug are uniformly distributed throughout the particles, and the microparticles do not show an initial excessive release of the drug, and are composed of uniform-sized particles having a particle size distribution width of 35 microns or less analyzed by a particle size analyzer and a specific surface area of the microparticles of 0.75×10−1 to 2.0×10−1 m2/g, thereby exhibiting a sustained release pattern of the drug. The injection composition comprising the drug contained in such microparticles can control the release of the drug for a selected period during injection administration to release an effective drug concentration constantly, and when formulated as an injection product, can reduce foreign body sensation and pain to the subject to enable an injection formulation with high compliance to be provided.
According to sustained-release microparticles containing deslorelin, and a preparation method therefor, of the present invention, sustained-release microparticles containing deslorelin in a formulation for subcutaneous administration are provided so that pain can be relieved during administration to animals, and a chemical castration effect can last for 2 to 36 months. In addition, the present invention is effective as a chemical castration agent for 2 to 8 months so as to have an excellent of removing boar taint.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/113 - Émulsions multiples, p. ex. huile-dans l'eau-dans l'huile
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
50.
SOLVENT-REMOVING APPARATUS AND METHOD FOR PRODUCING MICROSPHERES USING SAME
This solvent-removing apparatus comprises: a tank body accommodating an emulsion comprising first source material in a continuous phase and second source material in a dispersed phase; a fluid supply unit for supplying fluid into the tank body to cause the emulsion to circulate; and a discharge unit for discharging the gas in the tank body to the outside.
The present invention relates to an injectable composition for tissue repair and a method for preparing same, in which a short-term tissue repair effect and a long-term tissue repair effect by inducing collagen production can be provided, and skin health damaged by aging and irritation can be restored. The present invention also provides: an injectable composition for tissue repair, which is a ready-to-use injectable composition without the need for dilution before use, and thus can be immediately used, and is uniformly dispersed, thus exhibiting a uniform tissue repair effect; and a method for preparing same.
A61L 27/58 - Matériaux au moins partiellement résorbables par le corps
A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
52.
MICROSPHERE MANUFACTURING SYSTEM AND MICROSPHERE MANUFACTURING METHOD
A microsphere manufacturing system comprises: a first raw material storing unit for storing a first raw material; a second raw material storing unit for storing a second raw material including a solvent, a biodegradable polymer, and a drug; an emulsion generating unit for continuously forming an emulsion including the first raw material in a continuous phase and the second raw material in a dispersed phase; a first solvent extracting and removing unit which accommodates the emulsion formed by the emulsion generating unit, and extracts and removes the solvent from the dispersed phase of the emulsion so as to form microspheres; and a second solvent extracting and removing unit which is spaced apart from the first solvent extracting and removing unit, accommodates the emulsion formed by the emulsion generating unit, and extracts and removes the solvent from the dispersed phase of the emulsion so as to form microspheres.
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
The present invention provides sustained-release microparticles exhibiting a sustained release pattern of a drug, the microparticles comprising a biodegradable polymer and a drug, wherein the biodegradable polymer and drug are uniformly distributed throughout the entirety of the particles, and the microparticles do not exhibit initial burst release of the drug, have a particle size distribution width, analyzed by a particle size analyzer, of at most 35 microns, and are configured so as to have a uniform particle size by having a specific surface area of 0.75x10-1to 2.0x10-1m2/g. An injection composition comprising the drug contained in such microparticles controls the release of the drug during a selected duration when administered via injection so as to enable an effective concentration of the drug to be released at a constant rate, and, when formulated into an injection, may reduce foreign body sensation and pain in a subject, and thus an injection formulation having high compliance may be provided.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61K 31/485 - Dérivés du morphinane, p. ex. morphine, codéine
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
54.
Multichannel manufacturing device for mass production of microspheres
In the present invention, two adjacent supply lines for supplying two immiscible fluids are spirally disposed on a substrate where microchannels for microsphere production based on a droplet-based highly controlled method for mass-production of microspheres (HCMMM) are formed, and microsphere forming parts each comprising microchannels are arranged between and along the two supply lines, whereby a much larger amount of microspheres can be produced. Further, the two supply lines are disposed in a spiral configuration, and the microsphere forming parts can be disposed by branching microchannels from the two supply lines on inner and outer sides of the spiral configuration, whereby the limited space on a wafer normally having a circular shape can be maximally used to form multiple microsphere forming parts.
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
B01J 13/04 - Fabrication de microcapsules ou de microbilles par des procédés physiques, p. ex. séchage, pulvérisation
55.
SYSTEM FOR PRODUCING MICROPARTICLES, COMPRISING CARRIER FLUID, AND METHOD FOR CONTROLLING SAME
The invention disclosed in the present specification relates to a system for producing microparticles by using microfluidics and a method for controlling same and, in particular, provides: a system for producing microparticles, in which, as compared to the prior art, droplets produced using microfluidics can be stably transported without agglomerating or being destroyed; and a method for controlling the system so that the droplets can be more stably transported under the system. By the system for producing microparticles and the method for controlling same disclosed in the present specification, droplets produced by the system for producing microparticles by using microfluidics can be stably transported without agglomerating or being destroyed, thus enabling more efficient microparticle production.
The present invention relates to: sustained-release microparticles capable of maintaining, for a long time, effects of preventing, treating or alleviating benign prostatic hyperplasia and prostate cancer and effects of preventing hair loss and promoting hair growth according to the administration of microparticles containing dutasteride; and a preparation method therefor, and according to the use of a method for administering the particles to a patient through an injection, a patient does not have to directly store or handle the microparticles, unlike an oral dosage form, and thus storage and handling are simple. In addition, drug effects are maintained for a long period of time of 1-3 months and, simultaneously, administration through injection can be facilitated since foreign body sensation and pain are reduced when being administered to a patient through injection because of the constant average diameter of the particles.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The present disclosure relates to a sustained-release injectable composition comprising finasteride, and when the composition is injected as an injection formulation, it is possible to maintain a constant blood concentration for a long time without initial over-release in terms of the degree of release of finasteride, and when the composition is administrated by subcutaneous injection, it is possible to maintain the effect of treating hair loss and benign prostatic hyperplasia continuously for 1 to 3 months.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
58.
COMPOSITION FOR SUBCUTANEOUS INJECTION, CONTAINING DEOXYCHOLIC ACID, AND PREPARATION METHOD THEREFOR
The present invention relates to a composition for subcutaneous injection, containing deoxycholic acid, and a preparation method therefor. The present invention relates to a composition for non-surgical removal of localized fat deposits, the composition being micro-particles, which comprise deoxycholic acid and a biodegradable polymer, wherein the microparticles are formed such that deoxycholic acid is evenly distributed in a spherical biodegradable polymer. According to the present invention, a lipolysis effect lasts for 1 to 3 months from a single injection, a phenomenon in which surrounding tissues are destroyed during administration is prevented, and a drug release effect can be maintained at an effective amount of adipolysis concentration.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present invention relates to an injectable composition for tissue repair. According to the present invention, an injectable composition for tissue repair and a method for preparing same can be provided, in which the injectable composition as a ready-to-use injectable composition without the need for dilution before use induces an immediate tissue repair effect and collagen production, thus exhibiting a long-lasting tissue repair effect, and further comprises a polynucleotide, and thus can restore skin health damaged by aging and stimuli, through improvement in physiological environments in the body. In addition, in the injectable composition for tissue repair according to the present invention, natural extracts are uniformly mixed in microparticles using a biodegradable polymer, and thus, when the microparticles are injected as an injection, the occurrence of side effects such as inflammatory responses, edema, and dermal necrosis can be prevented.
In the present invention, two adjacent supply lines for supplying two immiscible fluids are spirally disposed on a substrate where microchannels for microsphere production based on a droplet-based highly controlled method for mass-production of microspheres (HCMMM) are formed, and microsphere forming parts each comprising microchannels are arranged between and along the two supply lines, whereby a much larger amount of microspheres can be produced. Further, the two supply lines are disposed in a spiral configuration, and the microsphere forming parts can be disposed by branching microchannels from the two supply lines on inner and outer sides of the spiral configuration, whereby the limited space on a wafer normally having a circular shape can be maximally used to form multiple microsphere forming parts.
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
61.
METHOD FOR PREPARING COMPOSITION POWDER FOR FEMININE WASH CONTAINING PROPOLIS AND NATURAL EXTRACT
The present invention relates to a method for preparing a composition powder for a feminine wash containing propolis and a natural extracts, wherein the composition powder for a feminine wash contributes to improvements in ease of use, convenience of storage, and shelf life of a composition product for a feminine wash.
A61K 8/98 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des produits de constitution indéterminée ou leurs dérivés d'origine animale
A61K 8/65 - CollagèneGélatineKératineLeurs dérivés ou produits de dégradation
A61K 8/49 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques contenant des composés hétérocycliques
The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 80-130 μm. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3 months to 6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
63.
SUSTAINED-RELEASE MICROPARTICLES CONTAINING DESLORELIN, AND PREPARATION METHOD THEREFOR
According to sustained-release microparticles containing deslorelin, and a preparation method therefor, of the present invention, sustained-release microparticles containing deslorelin in a formulation for subcutaneous administration are provided so that pain can be relieved during administration to animals, and a chemical castration effect can last for 2 to 36 months. In addition, the present invention is effective as a chemical castration agent for 2 to 8 months so as to have an excellent effect of removing boar taint.
The present invention provides a composition for subcutaneous injection containing microparticles comprising finasteride, the composition comprising: microparticles comprising finasteride and biodegradable polymer; and a suspension solvent. The composition for subcutaneous injection of the present invention is provided in a subcutaneously injectable form, not in an oral administration form, and thus there is no need for a user to store the composition, and a hair loss treatment effect by finasteride can be exhibited through a method of direct administration at a hospital, and thus ease of storage and handling is excellent. When microparticles comprising finasteride are administered using the composition for subcutaneous injection of the present invention, a long-term drug administration effect over a period of 1-3 months can be maintained. In addition, in the present invention, as the diameter of particles is formed to a uniform micro-size, the release of a drug from microparticles is controlled, thereby enabling an effective drug concentration to be constantly maintained, and the present invention can be provided as a composition for injection, in which, when applied to an injection consisting of a uniform size of particles and administered as an injection to a patient, the sense of foreign matter and pain are reduced.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
65.
Extended release microparticles comprising drug, and preparation method therefor
The present invention relates to extended release microparticles comprising a drug, and a preparation method therefor, and when the extended release microparticles comprising a drug are administered in order to replace conventional drugs that should be administered daily or monthly, the drug administration effect can be continuously maintained for one week to three months.
In addition, the drug administration effect is maintained for a long time and, simultaneously, microparticles are prepared so as to have the average diameter of a fixed micro-size, and thus an effective drug concentration can be constantly maintained by controlling the release of the drug from the microparticles, and a foreign body sensation and pain can be reduced during drug administration since microparticles having a uniform size are included during application as an injectable drug.
B01F 33/3011 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux utilisant un courant de gainage d'un fluide entourant un courant central d'un autre fluide, p. ex. pour réduire la section transversale du courant central ou pour produire des gouttelettes à partir du courant central
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
C08J 5/00 - Fabrication d'objets ou de matériaux façonnés contenant des substances macromoléculaires
B01J 2/06 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes en milieu liquide
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
66.
Microparticles containing finasteride and preparation method thereof
The present invention relates to microparticles containing finasteride, as microparticles containing finasteride and a biodegradable polymer, in a form in which the microparticles have a shape in which the finasteride drug is uniformly distributed in spherical biodegradable polymer particles, and the microparticles have an average particle diameter of 20 to 70 μm.
The present invention relates to sustained-release microparticles which can maintain the effect of treating alopecia sustainably for 1 month to 3 months as the microparticles containing finasteride are administered, and a preparation method thereof, and
the present invention may facilitate storage and handling of microparticles containing finasteride unlike oral dosage forms as a patient need not directly store and handle the microparticles by using the microparticles containing finasteride in a manner that the microparticles are administered to the patient through injection, maintain the drug effect for a long period of time such as 1 month to 3 months, and facilitate the administration as an injection by decreasing a foreign body sensation and pain at the time of administering the injection to a patient as the particles are prepared to have the average diameter of the particles to a certain micro size.
A61K 47/59 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes
A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
67.
Method for preparing pharmaceutical composition for preventing or treating cognitive impairment-related disease and pharmaceutical composition for preventing or treating cognitive impairment-related disease prepared by the same
The present invention relates to a method for preparing a pharmaceutical composition for preventing or treating a cognitive impairment-related disease and a pharmaceutical composition for preventing or treating a cognitive impairment-related disease prepared by the same, and the pharmaceutical composition includes microparticles including donepezil and a biodegradable polymer, and the microparticles are in a form in which donepezil is uniformly distributed in a spherical biodegradable polymer. The present invention may maintain the effect of preventing or treating the cognitive impairment-related disease for 1 month by a single injection in order to eliminate the inconvenience of having to take the composition daily, and as the present invention is prepared by maintaining the average diameters of the particles at a predetermined micrometer size, a foreign body sensation and pain during administration into a patient as an injection is reduced, thereby enabling administration as an injection to be facilitated.
Provided is an apparatus for a mass production of microspheres and a multichannel forming device incorporatable therein. The apparatus includes a multi-channel microsphere forming unit, a first source material reservoir containing the first source material and in fluid communication with the plurality of first microchannels, a second source material reservoir containing the second source material and in fluid communication with the plurality of second microchannels, a flow control unit configured to supply a first gas to the first source material reservoir at a first source material flow rate and to supply a second gas to a second source material reservoir at a second source material flow rate and a product reservoir for accommodating the microspheres formed from the multi-channel forming unit.
B01F 33/3011 - Micromixeurs utilisant des moyens spécifiques pour disposer les écoulements à mélanger, p. ex. des géométries ou des dispositions de canaux utilisant un courant de gainage d'un fluide entourant un courant central d'un autre fluide, p. ex. pour réduire la section transversale du courant central ou pour produire des gouttelettes à partir du courant central
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
C08J 5/00 - Fabrication d'objets ou de matériaux façonnés contenant des substances macromoléculaires
B01J 2/06 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes en milieu liquide
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
69.
MICROPARTICLES CONTAINING DUTASTERIDE, AND PREPARATION METHOD THEREFOR
The present invention relates to: sustained-release microparticles capable of maintaining, for a long time, effects of preventing, treating or alleviating benign prostatic hyperplasia and prostate cancer and effects of preventing hair loss and promoting hair growth according to the administration of microparticles containing dutasteride; and a preparation method therefor, and according to the use of a method for administering the particles to a patient through an injection, a patient does not have to directly store or handle the microparticles, unlike in an oral dosage form, and thus storage and handling are simple. In addition, drug effects are maintained for a long period of time of 1-3 months and, simultaneously, administration through injection can be facilitated since foreign body sensation and pain are reduced when being administered to a patient through injection because of the constant average diameter of the particles.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61P 13/08 - Médicaments pour le traitement des troubles du système urinaire de la prostate
The present invention relates to a composition for subcutaneous injection, containing deoxycholic acid, and a preparation method therefor. The present invention relates to a composition for non-surgical removal of localized fat deposits, the composition being microparticles, which comprise deoxycholic acid and a biodegradable polymer, wherein the microparticles are formed such that deoxycholic acid is evenly distributed in a spherical biodegradable polymer. According to the present invention, a lipolysis effect lasts for 1 to 3 months from a single injection, a phenomenon in which surrounding tissues are destroyed during administration is prevented, and a drug release effect can be maintained at an effective amount of adipolysis concentration.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COGNITIVE DISORDER-ASSOCIATED DISEASES, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING COGNITIVE DISORDER-ASSOCIATED DISEASES, PREPARED BY PREPARATION METHOD
The present invention relates to a method for preparing a pharmaceutical composition for preventing or treating cognitive disorder-associated diseases, and a pharmaceutical composition for preventing or treating cognitive disorder-related diseases, prepared by the preparation method, the pharmaceutical composition containing microparticles comprising donepezil and a biodegradable polymer, wherein the microparticles are formed such that donepezil is uniformly dispersed in a spherical biodegradable polymer. The present invention can maintain an effect of preventing or treating cognitive disorder-associated diseases for a month with one injection in order to solve the inconvenience of daily drug administration. In addition, since preparation is carried out such that the average diameter of particles is maintained in a predetermined micro-size, a foreign body sensation and pain are reduced during administration to a patient by injection, and thus administration by injection can be facilitated.
A61K 31/445 - Pipéridines non condensées, p. ex. pipérocaïne
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Infusions (medicinal -); implantable medicines;
pharmaceutical compositions; medicines for human purposes;
drugs for medical purposes; therapeutic drugs and agents;
chemical preparations for pharmaceutical purposes. Medical apparatus and instruments; medical instruments;
medical filler apparatus; medical apparatus and instruments
for administering pharmaceuticals; diagnostic apparatus and
instruments for medical purposes; injection device for
pharmaceuticals; apparatus for administering
pharmaceuticals. Biological research; biotechnological research; research
relating to pharmaceuticals; medical research in the field
of crude drugs; medical research; clinical studies of
medicines; scientific research for medical purposes; medical
and pharmacological research services; pharmaceutical
products development; research and development of technology
for biotechnology; research and development of medical
equipment.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Medicinal infusions for treating dementia, diabetes, obesity, andropathy, alopecia, incurable disease, chronic disease, lipolysis, and boosting the immune system; Medicinal infusions for treating dirofilaria immitis diseases, infectious diseases, skeletal and muscular disorders, cardiovascular and circulatory diseases, nervous system diseases, ocular disorders, respiratory diseases, gastrointestinal diseases, endocrine diseases, kidney diseases, hormonal diseases, and oncological diseases and disorders of animals; implantable medicines in the nature of surgical implants comprised of living tissues; pharmaceutical compositions for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical compositions for animal skincare; pharmaceutical compositions for skin care; pharmaceutical compositions for treating dirofilaria immitis diseases, infectious diseases, skeletal and muscular disorders, cardiovascular and circulatory diseases, nervous system diseases, ocular disorders, respiratory diseases, gastrointestinal diseases, endocrine diseases, kidney diseases, hormonal diseases, and oncological diseases and disorders of animals; medicines for human purposes, namely, medicines for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; drugs in the nature of pharmaceutical preparations for medical purposes, namely, for the treatment of oncological, gastrointestinal, metabolic, chronic, endocrine, respiratory, neurological and ophthalmic diseases and disorders; therapeutic drugs and agents in the nature of therapeutic pharmaceutical and agents for the treatment of oncological, gastrointestinal, metabolic, chronic, endocrine, respiratory, neurological and ophthalmic diseases and disorders; therapeutic drugs and agents in the nature of therapeutic pharmaceutical and agents for treating dirofilaria immitis diseases, infectious diseases, skeletal and muscular disorders, cardiovascular and circulatory diseases, nervous system diseases, ocular disorders, respiratory diseases, gastrointestinal diseases, endocrine diseases, kidney diseases, hormonal diseases, and oncological diseases and disorders of animals; chemical preparations for pharmaceutical purposes, namely, for the treatment of oncological, gastrointestinal, metabolic, chronic, endocrine, respiratory, neurological and ophthalmic diseases and disorders Medical apparatus and instruments for use in endovascular, cardiovascular, and endoscopy procedures; medical instruments for use in drug delivery systems; medical instruments for use in monitoring oxymetory, gas analysis, vital signs, blood properties and respiratory events; medical instruments for use in treating osteoarthritis, osteoporosis, osteotraumatic injuries, degenerative bone diseases and joint diseases; medical instruments to measure blood pressure, cardiac output and other physiological and cardiovascular parameters; medical instruments for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of cancer or other tissue-based diagnostic testing, cytology and cell-based testing; medical filler apparatus in the nature of synthetic filler and extender material to serve as replacement for bone; medical apparatus and instruments, namely, infusion and injection devices for administering pharmaceuticals; diagnostic apparatus and instruments for medical purposes, namely, medical diagnostic apparatus for testing blood sugar levels, cancer cells, DNA, urinary protein, and cholesterol level; injection device for pharmaceuticals; medical apparatus, namely, infusion and injection devices for administering pharmaceuticals
74.
EXTENDED RELEASE MICROPARTICLES COMPRISING DRUG, AND PREPARATION METHOD THEREFOR
The present invention relates to extended release microparticles comprising a drug, and a preparation method therefor, and when the extended release microparticles comprising a drug are administered in order to replace conventional drugs that should be administered daily or monthly, the drug administration effect can be continuously maintained for one week to three months. In addition, the drug administration effect is maintained for a long time and, simultaneously, particles are prepared so as to have the average diameter of a fixed micro-size, and thus an effective drug concentration can be constantly maintained by controlling the release of the drug from the microparticles, and a foreign body sensation and pain can be reduced during drug administration since microparticles having a uniform size are included during application as an injectable drug.
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
C08J 5/00 - Fabrication d'objets ou de matériaux façonnés contenant des substances macromoléculaires
B01J 13/06 - Fabrication de microcapsules ou de microbilles par séparation de phase
The present invention relates to microparticles comprising moxidectin and a biodegradable polymer, wherein the microparticles comprising moxidectin have a shape allowing a moxidectin drug to be uniformly distributed in spherical biodegradable polymer particles, and the average particle diameter of the microparticles is 80-130 μm. The present invention relates to: extended release microparticles capable of continuously maintaining a heartworm disease prevention effect for 3-6 months by administering microparticles comprising moxidectin; and a preparation method therefor. In addition, the present invention is prepared such that the average diameters of the particles have a predetermined micrometer size, and thus reduces a foreign body sensation and pain during administration into an animal through injection, thereby enabling administration through injection to be facilitated.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
76.
MICROPARTICLES INCLUDING FINASTERIDE, AND METHOD FOR PRODUCING SAME
The present invention relates to microparticles including finasteride and a biodegradable polymer, wherein the microparticles are in the form of spherical biodegradable polymer particles having finasteride medication uniformly distributed therein, and the average particle diameter of the microparticles is 20 to 70 µm. The present invention relates to: sustained-release microparticles, wherein the microparticles including finasteride can be administered to continuously maintain a hair-loss treatment effect for 1 to 3 months; and a method for producing the same. Moreover, the present invention involves administering the microparticles including finasteride to a patient via injections, and thus, unlike oral formulations, does not need to be stored or handled by the patient directly. Accordingly, storage and handling are convenient. The pharmaceutical effect of the microparticles is maintained for a long period of 1 to 3 months, and the microparticles are produced to have a uniform and micro-size average particle diameter. As a result, the irritation and pain when administering the microparticles to a patient as an injection are reduced, and thus the microparticles can be easily administered as an injection.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
Provided is an apparatus for a mass production of microspheres and a multichannel forming device incorporatable therein. The apparatus comprises a multi-channel microsphere forming unit, a first source material reservoir containing the first source material and in fluid communication with the plurality of first microchannels, a second source material reservoir containing the second source material and in fluid communication with the plurality of second microchannels, a flow control unit configured to supply a first gas to the first source material reservoir at a first source material flow rate and to supply a second gas to a second source material reservoir at a second source material flow rate and a product reservoir for accommodating the microspheres formed from the multi-channel forming unit.
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
C08J 5/00 - Fabrication d'objets ou de matériaux façonnés contenant des substances macromoléculaires
B01J 2/06 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes en milieu liquide
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
78.
Apparatus for a mass production of monodisperse biodegradable polymer-based microspheres and a multi-channel forming device incorporatable therein
A method and an apparatus for a large-scale production of monodisperse microspheres and biodegradable polymer-based drug delivery systems and design optimization method for the apparatus are provided. The method uses a plurality of microchips, each microchip having at least a first pathway, a second pathway and an outlet, wherein the first pathway and the second pathway merge at a cross point being one end of the outlet, and the method comprises preparing a polymer-phase solution including a degradable polymer and a water-phase solution including a surfactant, having the polymer-phase solution flow through the first pathway, having the water-phase solution flow through the second pathway, gathering a mixed solution flowing out of the outlet, and collecting the microspheres by filtering out the water-phase solution.
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
B01F 13/00 - Autres mélangeurs; Installations pour effectuer des mélanges comportant des combinaisons de mélangeurs de types différents
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
B01J 2/06 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes en milieu liquide
B01J 13/06 - Fabrication de microcapsules ou de microbilles par séparation de phase
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/58 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine
C08J 5/00 - Fabrication d'objets ou de matériaux façonnés contenant des substances macromoléculaires
B01J 2/02 - Procédés ou dispositifs pour la granulation de substances, en généralTraitement de matériaux particulaires leur permettant de s'écouler librement, en général, p. ex. en les rendant hydrophobes par division du produit liquide en gouttelettes, p. ex. par pulvérisation, et solidification des gouttelettes
79.
APPARATUS FOR A MASS PRODUCTION OF MONODISPERSE BIODEGRADABLE POLYMER-BASEDMICROSPHERES AND A MULTI-CHANNEL FORMING DEVICE INCORPORATABLE THEREIN
Provided is an apparatus for a mass production of microspheres and a multichannel forming device incorporatable therein. The apparatus comprises a multi-channel microsphere forming unit, a first source material reservoir containing the first source material and in fluid communication with the plurality of first microchannels, a second source material reservoir containing the second source material and in fluid communication with the plurality of second microchannels, a flow control unit configured to supply a first gas to the first source material reservoir at a first source material flow rate and to supply a second gas to a second source material reservoir at a second source material flow rate and a product reservoir for accommodating the microspheres formed from the multi-channel forming unit.
B01J 13/04 - Fabrication de microcapsules ou de microbilles par des procédés physiques, p. ex. séchage, pulvérisation
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en généralAppareils appropriés
80.
OPTIMIZATION OF THE DESIGNING OF APPARATUS AND PROCESSES FOR MASS PRODUCTION OF MONODISPERSE BIODEGRADABLE POLYMER-BASED MICROSPHERES AND BIODEGRADABLE POLYMER-BASED DRUG DELIVERY SYSTEMS
a method and an apparatus for a large-scale production of monodisperse microspheres and biodegradable polymer-based drug delivery systems and design optimization method for the apparatus are provided. The method uses a plurality of microchips, each microchip having at least a first pathway, a second pathway and an outlet, wherein the first pathway and the second pathway merge at a cross point being one end of the outlet, and the method comprises preparing a polymer-phase solution including a degradable polymer and a water-phase solution including a surfactant, having the polymer-phase solution flow through the first pathway, having the water-phase solution flow through the second pathway, gathering a mixed solution flowing out of the outlet, and collecting the microspheres by filtering out the water-phase solution.
The present invention relates to a preparation method of microparticles comprising a biodegradable polymer wherein the microparticles prepared according to the present invention are spherical microparticles for injection into the skin. The size of the microparticles can be controlled by using the preparation method. In addition, the microparticles comprising a biodegradable polymer can be produced in a narrow range of size and thus can exhibit a high production yield rate. Considering the characteristic in which a dissolution rate varies according to the size of the microparticles, the dissolution rate can be controlled after injecting the microparticles, prepared according to the present invention, into a body.
Provided is a droplet discharging device that can precisely dispense large flow rate of droplets and small flow rate of droplets selectively. The droplet discharging device according to the present invention includes a pneumatic discharger for discharging a droplet having a first flow rate, and an electronic pipette for discharging or sucking a droplet having a second flow rate equal to or smaller than the first flow rate. The pneumatic discharger includes, i) a storage chamber for storing a liquid, ii) an air tank connected to the storage chamber through a first air pipe and supplying compressed air to the storage chamber to push the liquid of the storage chamber outside, and iii) a first nozzle connected to the storage chamber through the liquid pipe and receiving the liquid pushed out of the storage chamber to discharge droplets.
